Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

The Journal of antimicrobial chemotherapy - 1 May 2000

Pestova E, Millichap J J, Noskin G A, Peterson L R

Abstract excerpt

The in vitro activity of the novel 8-methoxyquinolone, moxifloxacin, against Streptococcus pneumoniae was evaluated, and the intracellular targets of this agent were studied. Analysis of mutant strains selected with moxifloxacin demonstrated that first-step mutants bore amino acid substitutions at position 81 in the GyrA subunit of DNA gyrase. This suggests that, unlike older fluoroquinolone agents such as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Aza Compounds
Share to DNA Topoisomerases, Type I

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Topoisomerases, Type II

Share to Fluoroquinolones

Share to Moxifloxacin

Share to Pneumococcal Infections

Share to Quinolines

Source

Identifiers

PMID: 10797078
DOI: 10.1093/jac/45.5.583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.PMID 10797078Read ↗

Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.Semantic proximity Read ↗

In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.Semantic proximity Read ↗

Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.Semantic proximity Read ↗

The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.Semantic proximity Read ↗

Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

Activity of and resistance to moxifloxacin in Staphylococcus aureus.Semantic proximity Read ↗

Relative potential for selection of quinolone-resistance-determining-region mutations in Streptococcus pneumoniae by gemifloxacin, gatifloxacin and moxifloxacin.Semantic proximity Read ↗

Identification and characterization of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus.Semantic proximity Read ↗

In vitro activity of moxifloxacin compared to other fluoroquinolones against different erythromycin-resistant phenotypes of group A beta-hemolytic streptococcus.Semantic proximity Read ↗

Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.Semantic proximity Read ↗

Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.Semantic proximity Read ↗

Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.